Sanofi India Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Rodolfo Hrosz
Chief executive officer
₹36.4m
Total compensation
| CEO salary percentage | 62.5% |
| CEO tenure | 2.8yrs |
| CEO ownership | n/a |
| Management average tenure | 1.5yrs |
| Board average tenure | 4.1yrs |
Recent management updates
Recent updates
Investors Can Find Comfort In Sanofi India's (NSE:SANOFI) Earnings Quality
Mar 07
Benign Growth For Sanofi India Limited (NSE:SANOFI) Underpins Its Share Price
Feb 15Sanofi India Limited's (NSE:SANOFI) 25% Share Price Surge Not Quite Adding Up
Jun 11Sanofi India (NSE:SANOFI) Will Pay A Dividend Of ₹117.00
Apr 26Sanofi India (NSE:SANOFI) Will Pay A Dividend Of ₹117.00
Apr 12Sanofi India (NSE:SANOFI) Is Due To Pay A Dividend Of ₹117.00
Mar 29Sanofi India's (NSE:SANOFI) Dividend Will Be ₹117.00
Mar 09Risks To Shareholder Returns Are Elevated At These Prices For Sanofi India Limited (NSE:SANOFI)
Dec 21Is Sanofi India (NSE:SANOFI) A Risky Investment?
May 26Does Sanofi India (NSE:SANOFI) Have A Healthy Balance Sheet?
May 10Sanofi India (NSE:SANOFI) Is Increasing Its Dividend To ₹490
Apr 02Sanofi India (NSE:SANOFI) Is Increasing Its Dividend To ₹490
Feb 25Estimating The Fair Value Of Sanofi India Limited (NSE:SANOFI)
Dec 10CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | n/a | n/a | ₹3b |
| Sep 30 2024 | n/a | n/a | ₹5b |
| Jun 30 2024 | n/a | n/a | ₹5b |
| Mar 31 2024 | n/a | n/a | ₹5b |
| Dec 31 2023 | ₹36m | ₹23m | ₹6b |
| Sep 30 2023 | n/a | n/a | ₹6b |
| Jun 30 2023 | n/a | n/a | ₹6b |
| Mar 31 2023 | n/a | n/a | ₹6b |
| Dec 31 2022 | ₹18m | ₹13m | ₹6b |
Compensation vs Market: Rodolfo's total compensation ($USD423.14K) is about average for companies of similar size in the Indian market ($USD489.25K).
Compensation vs Earnings: Rodolfo's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
CEO
Rodolfo Hrosz (57 yo)
2.8yrs
Tenure
₹36,390,000
Compensation
Mr. Rodolfo Hrosz serves as Managing Director and Director for Sanofi India Limited since June 1, 2022. He joined Sanofi as General Manager of the Consumer Healthcare business in Brazil in 2017 and has suc...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD & Director | 2.8yrs | ₹36.39m | no data | |
| CFO & Whole Time Director | 1.3yrs | ₹1.51m | no data | |
| Additional Whole Time Director | 1.5yrs | ₹1.85m | no data | |
| Senior Director of Accounting & Taxation | 41.1yrs | no data | no data | |
| Company Secretary & Compliance Officer | less than a year | no data | no data | |
| People & Culture Director | 1.4yrs | no data | no data | |
| Head of Country Procurement - India | 11.2yrs | no data | no data | |
| Senior Director of Public Affairs | no data | no data | no data | |
| Senior Director of Regulatory Affairs | no data | no data | no data | |
| Sales & Customer Engagement Head - Diabetes and Senior Director of Diabetes | no data | no data | no data |
1.5yrs
Average Tenure
62yo
Average Age
Experienced Management: SANOFI's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD & Director | 2.8yrs | ₹36.39m | no data | |
| CFO & Whole Time Director | 1.3yrs | ₹1.51m | no data | |
| Additional Whole Time Director | 1.5yrs | ₹1.85m | no data | |
| Independent Non-Executive Director | 8.9yrs | ₹2.68m | no data | |
| Independent Director | 4.7yrs | ₹3.04m | no data | |
| Independent Non-Executive Chairman | 8.9yrs | ₹3.54m | no data | |
| Non-Executive Director | 4.1yrs | ₹20.23m | no data |
4.1yrs
Average Tenure
66yo
Average Age
Experienced Board: SANOFI's board of directors are considered experienced (4.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/23 22:03 |
| End of Day Share Price | 2025/03/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sanofi India Limited is covered by 13 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sarabjit Nangra | Angel Broking Private Limited |
| Rohit Bhat | Batlivala & Karani Securities India Pvt. Ltd. |
| Ranjit Kapadia | Centrum Broking Limited |